Beam Therapeutics Inc. (BEAM)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Beam Therapeutics’ EPS trailed consensus in the third fiscal quarter of 2026, reported November 3, 2026, with EPS of -$1.28 trailing the -$1.15 estimate by -$0.13 and deteriorating from -$1.10 a year ago (a -16.4% year-over-year change). The quarter’s net loss widened as net income fell 19.2% year over year to roughly -$134.4 million (down from -$112.7 million a year ago), alongside an operating loss of about -$141.3 million, as the company continued investing across its gene-editing pipeline programs including BEAM-101, BEAM-102, BEAM-201, and BEAM-301. Cash generation remained negative, with negative operating cash flow of around -$110.7 million. For the next period, consensus calls for EPS of -$1.25 on revenue of $7.9 million.
About Beam Therapeutics Inc.
Beam Therapeutics Inc. develops gene-editing medicines in biotechnology, focused on precise genetic remedies for severe diseases. The company, which trades on NASDAQ as BEAM, recorded $139.7 million in revenue in FY2025. Its work centers on engineered therapies for blood disorders and other serious conditions, with operations based in the United States.
Today's Snapshot
BEAM closed 1.7% higher at 21.01, outperforming a weaker sector. Trading was busier than usual, with volume roughly twice its usual level. Beam Therapeutics advanced BEAM-302, a gene-editing treatment, toward late-stage testing.
Trading Volume
Above 10d avg 2.7M
4.8M
vs S&P 500 Today
Outperforming Market
+2.00%
Updated: November 18, 2026 at 21:25 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$23.26 - $27.00Sell
- RSI (14)36.17Neutral
- Stochastic %K (14, 3, 3)3.34Buy
- MACD Level (12, 26)-0.96Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.